Silence Therapeutics PLC · NASDAQ:SLN
Silence Therapeutics — H1 2020 Earnings Presentation
12 slides from Silence Therapeutics's earnings presentation, Sep 14, 2020
Slide 1: Silence Therapeutics H1 2020 Results
Silence Therapeutics H1 2020 Results September 14, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements The information contained in this presentation is being supplied and communicated to you solely This presentation may contain forward-looking statements that reflect the Company’s current for your information and may not be reproduced, further distributed to any other pers
Slide 3: H1 2020 & Recent Highlights
H1 2020 & Recent Highlights Advanced proprietary pipeline programmes • SLN360 IND approved by FDA to start Phase 1 studies • Started dosing in SLN124 Phase 1 trial Secured major new collaborations • AstraZeneca • Takeda • Expanded partnership with Mallinckrodt Strong balance sheet • Projected cash r
Slide 4: Appointed Mark Rothera President and CEO
Appointed Mark Rothera President and CEO • Over 30 years of broad, global biopharma experience • Record of strong commercial and operational leadership, including successfully growing multiple biotechnology companies • Previously, CEO of Orchard Therapeutics, a leading publicly- traded gene therapy
Slide 5: Advancing Proprietary Pipeline Programmes
Advancing Proprietary Pipeline Programmes © Silence Therapeutics 2020 5
Slide 6: SLN360: wholly owned product candidate for cardiovascular disease with high Lp(a)
SLN360: wholly owned product candidate for cardiovascular disease with high Lipoprotein(a) or Lp(a) • High Lp(a) levels* affects ~20% of the world's population The Opportunity • Apheresis is the only approach that can appreciably reduce Lp(a) levels, but it is invasive and burdensome How SLN360 is •
Slide 7: SLN124: wholly owned product candidate for beta-thalassaemia and MDS
SLN124: wholly owned product candidate for beta-thalassaemia and myelodysplastic syndrome (MDS) • Potential to reduce transfusion burden due to iron- The Opportunity overload associated ineffective erythropoiesis How SLN124 is • Reducing TMPRSS6 gene expression to up-regulate Designed to Work hepcid
Slide 8: SLN124 Phase 1 Program Overview
SLN124 Phase 1 Program Overview Phase 1: Healthy Volunteers • Design: Phase 1 randomised, double-blind, placebo controlled, single-ascending dose study • Population: up to 24 healthy volunteers Phase 1b: Thalassaemia and VL/LR-MDS • Design: Phase 1b global, randomised, single-blind, placebo-controll
Slide 9: Corporate Collaborations
Corporate Collaborations © Silence Therapeutics 2020 9
Slide 10: High-Value Collaborations – Expanding Pipeline Opportunities
High-Value Collaborations – Expanding Pipeline Opportunities • Signed major deal to discover, develop and commercialise siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases in March 2020 • Upfront cash payment of $60 million and an equity investment of $20 million1 • Up t
Slide 11: H1 2020 Financial Highlights
H1 2020 Financial Highlights • Loss after tax of £11.0 million (H1 2019: £8.2 million) with an increase in operating costs compared to H1 Income statement (GBP '000) H1 2020 H1 2019 2019 driven by increasing R&D spend with both SLN360 and SLN124 being prepared for clinical testing this year Revenue
Slide 12: Q & A
Q&A © Silence Therapeutics 2020 12